Developing Multi-Omic Biomarker Strategies for Assessing Sensitivity of RASTargeting Drugs for More Efficacious Therapies
- Uncovering the impact of genomics on RAS inhibitor sensitivity
- Highlighting how transcriptional signatures may affect sensitivity to RAS targeting drugs
- Predicting RAS sensitivity through proteomic biomarkers and pathway analysis to advance more effective RAS-targeting drugs and combinations